Late Boosting of the RV144 Regimen with AIDSVAX B/E and ALVAC-HIV in HIV-Uninfected Thai Volunteers, a Randomised Controlled Trial

Autor: Piyathida Sroysuwan, Natthapol Kosashunhanan, Sebastian Molnar, Jerome H. Kim, Alexandra Schuetz, Taweewat Supindham, Elizabeth Heger, Sandhya Vasan, Phiromrat Rakyat, Suwat Chariyalertsak, Nittaya Phanuphak, Siriluck Teerachia, Suchada Chinaworapong, Nongluck Sangnoi, Oranitcha Kaewthip, Sorachai Nitayaphan, Surat Jongrakthaitae, Pornchanok Panjapornsuk, Michael A. Eller, Puttachard Saengtawan, Weerawan Chuenarom, Nuntisa Chotirosniramit, Pornsuk V. Grandin, Sirinan Madnote, Benjaluck Phonrat, Rungsun Rerknimitr, Narongrid Sirisopana, Lindsay Wieczorek, Siriwat Akapirat, Chirapa Eamsila, Faruk Sinangil, Kirsten Smith, James Tartaglia, Poonam Pegu, Dohoon Kim, Carter Lee, Peter Dawson, Saowanit Getchalarat, Robert J. O'Connell, Nicos Karasavvas, Jiraporn Puangkaew, Patcharaphan Sugandhavesa, Nitiya Chomchey, Punnee Pitisuttithum, Jean-Louis Excler, Boonlure Pruenglampoo, Yingjun Zhou, Yupa Sabmee, Jittima Dhitavat, Merlin L. Robb, Jesse Schoen, Victoria R. Polonis, Nelson L. Michael, Boot Kaewboon, Nipat Teeratakulpisarn, Bessara Nuntapinit, Wanlaya Labwech, Eugene Kroon, Viseth Ngauy, Prapaporn Savaraj, Jaranit Kaewkungwal, Pawinee Jarujareet, Nampueng Churikanont, Surawach Rittiroongrad, Somsak Chantakulkij, Anant Phramtong, Rapee Trichavaroj, Carlos A. DiazGranados, Silvia Ratto-Kim, Sanjay Phogat, Mark de Souza, Arom Pitisuthitham, Nipattra Tragonlugsana

Publikováno v: Lancet HIV

BACKGROUND: The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX® B/E administration over six months resulted in a 31% efficacy in preventing HIV acquisition. In this trial, we assessed the immunologic impact

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f962459539bb0b1f931c1b9f15f516
https://europepmc.org/articles/PMC7247755/